This article is a continuation of the "Do You Know Your Guidelines" series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are reviewed here, including the critical roles of radiotherapy, chemotherapy, and the recent application of immunotherapy agents. We will be limiting this discussion to include cancers of the oral cavity, oropharynx, hypopharynx, and larynx. It should be noted that much of the article pertains to human papillomavirus (HPV)-negative oropharyngeal cancer where applicable, as HPV-positive oropharyngeal squamous cell carcinoma carries a different natural history, different prognosis, and now different staging criteria. Additionally, the article will not include information on nasopharyngeal or sinus cancers, as these latter topics are covered in separate "Do you know your guidelines?" installments and these diagnoses carry somewhat different approaches to diagnosis and management that diverge from the focus of this article.
1.1 | How is "advanced disease" defined in head and neck squamous cell carcinoma?
"Advanced disease" as it relates to HNSCC can be defined several ways, depending on the context. This review focuses on 4 clinical settings in which HNSCC disease progression can be considered "advanced": (1) postoperative "high-risk" HNSCC; (2) potentially resectable locoregional disease; (3) locoregionally unresectable disease; and (4) distantmetastatic HNSCC. The management of recurrent HNSCC will also be discussed briefly, although this subject is a topic of a separate article in the series. Two clinical features have been generally agreed upon to define "high-risk, resected disease": when extranodal extension (ENE) is present, and second, the presence of disease at the surgical margins of resection. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Newly diagnosed unresectable disease is defined generally as T4b classification (stage group IVB) tumors, according to the AJCC TNM staging system.
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"Unresectable" tumors are typically those that cannot be removed without causing unacceptable morbidity, such as tumors with dense involvement of the cervical vertebrae, brachial plexus, deep muscles of the neck, base of skull, or carotid artery. Subsequently, we will discuss treatment of patients with distant metastatic HNSCC and, finally, we will review guidelines for treatment of HNSCC tumors that persist or recur after attempted primary treatment.
| What are the guidelines for treatment of high-risk resectable head and neck squamous cell carcinoma?
After surgical resection with curative intent, adjuvant therapy with postoperative radiotherapy (PORT) to the local and regional sites of disease is the standard of care for patients with AJCC stage III or IV HNSCC; that is for patients with T3 or T4 local disease and/or for patients with stage N2a or greater nodal metastases. 2 As stated above, the presence of ENE and positive surgical margins are generally accepted as indicators of disease that is at "high-risk" of recurring both locoregionally or distantly. After resection, additional treatment is indicated for this high-risk group to reduce these risks. Moreover, adjuvant radiation is also recommended if patients have significant perineural or lymphovascular invasion identified on pathologic evaluation. 2 For patients with positive surgical margins, if additional resection can be carried out with a high likelihood of achieving a complete surgical resection without long-term complications, then re-resection is recommended. 2 For patients with positive margins that cannot be cleared surgically, and/or for patients with ENE, postoperative adjuvant chemoradiotherapy (CRT) with concurrent cisplatin treatment is indicated. 2 The evidence for the use of postoperative adjuvant CRT compared to radiotherapy (RT) alone derives from 2 large phase III trials, the Radiation Therapy Oncology Group (RTOG #9501) study 17 and the European Organization for
Research and Treatment of Cancer (EORTC #22931) study, 18 detailed below.
Although each trial had similar purposes, the definition of high-risk disease and inclusion criteria differed between these 2 studies. The EORTC (#22931) trial included not only patients with T1/T2 and N0/N1 disease with the above-noted high-risk features, but also enrolled patients without highrisk pathological findings. 18 Patients were included if they had T3/T4 tumors regardless of nodal involvement (except T3N0 of the larynx) with negative margins, or T1/T2 tumors with N2/N3 disease. For this trial, high-risk features comprised of the following: ENE; positive resection margins; perineural involvement; or vascular tumor embolism. The RTOG (#9501) trial selectively included patients with defined high-risk features, including histologic evidence of invasion of 2 or more regional lymph nodes, ENE, and microscopically involved mucosal margins of resection.
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Both studies concluded that the addition of cisplatin to PORT benefited patients with high-risk HNSCC. The EORTC (#22931) study demonstrated significant improvement in both progression-free survival and overall survival (OS) in the combined-therapy group. In the RTOG (#9501) study, locoregional control was improved and disease-free survival was significantly longer after combined therapy; however, OS did not differ significantly between the 2 study groups. Postoperative CRT carries a high burden of toxicity and potential morbidity to patients. Therefore, to determine which patients would maximally benefit from receiving postoperative adjuvant CRT, a meta-analysis of EORTC (#22931) and RTOG (#9501) was published.
19 This metaanalysis concluded that patients with nodal ENE and/or positive surgical margins derived a significant OS benefit from combined therapy over RT alone. When neither of these risk factors was present, there was no significant survival advantage observed as a result of postoperative adjuvant CRT compared to PORT alone. Furthermore, in a long-term follow-up to RTOG (#9501), at a median time of 9.4 years, the only significant difference in locoregional control and disease-free progression was detected in the subgroup of patients with ENE and/or positive surgical margins. 20 For patients with an ECOG PS of 0 or 1, the recommendations include concurrent systemic therapy (cisplatin is the preferred agent) and radiation, or induction chemotherapy followed by either RT alone or RT and additional systemic therapy. The controversy regarding the additional benefit that induction chemotherapy offers to these patients is discussed below. Patients with an ECOG PS of 2 should undergo definitive RT with or without concurrent systemic therapy, depending on the perceived ability of the patient to tolerate chemotherapy. With an ECOG PS of 3, goals shift toward palliative treatment either with RT, single agent systemic therapy, or supportive care alone to manage symptoms and provide comfort. 2 Such patients with severe functional decline are treated in a comparable manner as those with incurable recurrent or metastatic disease, which is discussed later in this review. Concurrent cisplatin-based CRT remains one of the more substantially supported options for managing unresectable advanced HNSCC or for patients who cannot tolerate surgery. A standard treatment approach uses high-dose cisplatin on days 1, 22, and 43 during RT and has been found to be effective and easy to administer, and a low-dose weekly administration schedule of cisplatin is also used. 39 or carboplatin/paclitaxel. 40 Unfortunately, there is a lack of quality studies comparing differences between these individual systemic therapies plus RT with respect to one another, and, therefore, there is no established superiority of 1 regimen over others. Evidence behind the recommendation for use of concurrent chemotherapy and RT derives from many randomized trials [41] [42] [43] [44] [45] [46] [47] and several meta-analyses. [48] [49] [50] [51] [52] The more significant of these, the large Meta-Analysis of Chemotherapy on Head and Neck Cancer, was recently updated in 2016. [49] [50] [51] [52] The recent update in 2016 52 analyzed 94 trials (18 934 patients) comparing local RT alone to RT plus concurrent/ alternating chemotherapy, or induction chemotherapy followed by concurrent CRT. The addition of chemotherapy to RT led to improved OS versus RT alone, but this benefit was limited to concomitant CRT, not induction chemotherapy, translating into a 5-year and 10-year absolute survival benefit of 6.5% and 3.5%, respectively. Nevertheless, potential benefits of induction chemotherapy remain unclear. Induction chemotherapy may allow for 51 Additional rationale behind induction chemotherapy include possible increase in the efficacy of subsequent CRT resulting from its downstaging effects on the gross tumor volume and that it may act as a test of tumor radiosensitivity. 53 These potential advantages have driven continued active research focusing on the utility of induction chemotherapy in HNSCC. [53] [54] [55] [56] [57] A triplet chemotherapy regimen (cisplatin plus, 5-fluorouracil, and a taxane) revealed improved responses over cisplatin/5-fluorouracil, [58] [59] [60] [61] [62] [63] [64] and for docetaxel-containing regimens, 59 improved OS, which has led to US Food and Drug Administration (FDA) approval of docetaxel for HNSCC and further exploration of cisplatin plus, 5-fluorouracil, and a taxane as an induction regimen. Despite this recent emphasis on triplet chemotherapy as an induction strategy, the current literature has not yielded consistent results in favor of this approach. If induction chemotherapy followed by CRT is used, evidence is in favor of the addition of a docetaxel to cisplatin/5-fluorouracil. 2 Due to high toxicity, it is not recommended to follow cisplatin-based induction with cisplatin-based CRT. 2, 65, 66 Recommended agents for CRT after induction include weekly carboplatin or cetuximab. The standard treatment of patients with HNSCC who are determined to have distant metastases at first diagnosis should be largely dictated by the patient's performance status, personal goals, comorbidities, potential cost, and consideration of toxicities and prognosis. Treatment options for these patients include combination systemic chemotherapy, single agent chemotherapy, palliative RT, or best supportive care.
2 Enrollment in clinical trials is preferred, if possible. The multidrug regimens included above generally improve response rates over single agents, but until the addition of cetuximab have never been shown to improve survival over single-agent approaches. 2 Response rates for single-agent chemotherapeutics for recurrent or metastatic disease is about 10%-20% with a modest increase in response (30%-40%) when platinum-based combination regimens are selected. 89 Only a few studies have described differences between using multiple cytotoxic agents and single agents. One such study by Jacobs et al, 75 reported a phase III study involving patients with recurrent or metastatic HNSCC randomized to cisplatin alone, 5-fluorouracil only, or the combination once every 3 weeks. The overall response rate (ORR) improved with the combination; however, the median survival remained at 5.7 months for all groups. The Southwest Oncology Group conducted a similar phase III trial 74 85 Capecitabine is a prodrug that is converted to its only active metabolite, fluorouracil, by thymidine phosphorylase. 87 Higher levels of this enzyme are found in several tumors and the liver, compared with normal healthy tissue. Both of these drugs have low level recommendations by the NCCN for use in recurrent or metastatic disease in patients who have had disease progression on platinum-based therapy. 2 Afatinib has more robust data with a published phase III study, 86 whereas use of capecitabine is advised based on evidence from phase II studies. 87, 88 Research toward the utility of these agents in the setting of failure after more substantiated regiments is ongoing. Figure 1) . Alternatively, if the disease is resectable but surgery is not performed, similar schedules of CRT that are used for treatment-naïve disease, as mentioned in a preceding section, are indicated. 2 The rationale supporting salvage surgery for patients with resectable recurrent or persistent disease is a complex topic and exceeds the scope of this article; but it is important to address a few aspects. Salvage surgery may offer a high chance of long-term disease control and a possible cure to select patients, yet morbidity from surgery in this setting can result in significant pain and cost with marginal benefit in survival. 89 Salvage procedures often result in reduction or permanent loss of function of important head and neck structures (ie, the larynx, pharynx, oral cavity, etc), leading to significant cosmetic detriments, high economic burden, and even death. One of the most difficult, but critical, questions is determining which patients will maximally benefit from salvage surgery while reducing potential harms as much as possible. An extensive informed discussion must occur between the surgeon and patient, particularly assessing prognostic factors that may help guide expectations and choice of suitable surgical candidates. The patient's comorbidities, life expectancy, performance status, speech and swallowing function, nutritional status, and severity of current symptoms need to be evaluated. Significant prognostic factors that should be considered to facilitate management decisions include recurrent stage, [90] [91] [92] recurrent site, 90,91 disease-free interval, initial treatment by chemoradiation, and locoregional versus limited local recurrence. 91 Improved outcomes after salvage surgery have been noted in patients with lower stage disease, [90] [91] [92] disease-free interval >6 months, 91 initial treatment with radiation alone compared to CRT, 91 and laryngeal recurrence in respect to other subsites. 90, 92 If previous treatment with radiation was performed, and the disease is unresectable, management includes reirradiation with or without chemotherapy, chemotherapy alone, or best supportive care. 2 Regimens for CRT or chemotherapy Reirradiation may also be considered in the postoperative setting. The efficacy of reirradiation may be negatively affected by local scarring and fibrosis from previous radiation, as well as difficulty in achieving adequate dosage because of the proximity to vital structures, which are already near tissue tolerance. Additionally, recurrence implies a degree of radiation resistance if the initial therapy was properly administered. Reirradiation should be carefully considered because of an increase in acute and late toxicities. 2 Janot et al 93 reported on 130 patients with HNSCC who previously underwent surgery for a recurrence or a second primary tumor in a previously irradiated area who were randomly assigned to either full-dose reirradiation combined with chemotherapy or to observation only. Patients in the reirradiation arm received 60 Gy over 11 weeks combined with concomitant fluorouracil and hydroxyurea. A significant difference in locoregional control was found between the 2 groups, in favor of the reirradiation arm. Disease-free survival was significantly improved in the chemotherapy plus reirradiation arm, but the OS was not statistically different. At 24 months, 39% of the patients in the RT arm and 10% in the observation arm experienced grade 3 or 4 late toxicity. The main grade 3 and 4 late toxicities were sclerosis, trismus, and osteoradionecrosis. The higher likelihood of increased toxicity should be strongly considered if treating with reirradiation (with or without concurrent chemotherapy) for the potential benefit to locoregional control and disease-free survival.
| What are the recommendations regarding follow-up?
Despite aggressive treatment of advanced disease, locoregional recurrences develop in 30%-40% of patients and distant metastases occur in 20%-30%. 91, 92 These patients also have an elevated risk of developing a second primary cancer if they have pronounced smoking and/or alcohol history. These second primaries more commonly consist of lung or upper aerodigestive tract cancers, but also include head and neck malignancies. 94, 95 Posttreatment surveillance assumes that early recurrence detection can improve outcomes among patients with advanced HNSCC. However, the literature regarding head and neck cancer suggests that regular followup is not significantly associated with improved survival outcomes. [96] [97] [98] [99] Nonetheless, proper follow-up is essential for monitoring any recurrence or development of a second primary, assessing treatment results, managing acute and chronic treatmentrelated side effects, providing tobacco education, monitoring for psychosocial well-being, meeting any needs for speech or swallow treatment, and offering emotional and morale support. A follow-up schedule must be tailored to the individual patient based on the stage of disease at diagnosis, extent of treatment received, the site of the tumor, and patient variables, including age and comorbidities.
The NCCN guidelines recommend complete clinical examination and physical, including fiber-optic examination, every 1-3 months for the first year, every 2-6 months for the second year, every 4-8 months between years 3 and 5, and annually thereafter. Thyroid stimulating hormone tests should be ordered every 6-12 months if irradiation of the neck occurred. For patients 50 years or older with >20 packyear history of smoking, initial screening recommendations include a low-dose CT chest, followed by annual low-dose CT chest scans for 2 years. 2 Continued routine imaging may be indicated based on sign/symptoms or desire to assess areas inaccessible to clinical examination. A posttreatment baseline imaging using positron emission tomography (PET)/CT is recommended for patients with T3/T4 or N2/N3 cancers of the oropharynx, hypopharynx, larynx, and nasopharynx. This PET/CT should be within 6 months of treatment but is ideally performed approximately 12 weeks after the last treatment. 3) in the planned-surgery group. The hazard ratio for death with surveillance as compared with planned surgery was 0.92 (95% CI 0.65-1.32). This study suggests that there may be a role for PET/CT in follow-up for patients with severe nodal disease to monitor for recurrence, sparing routine neck dissections for patients. More information on the question of routine surveillance imaging on asymptomatic patients and additional follow-up interventions may be found in the follow-up and surveillance entry in this series. 101 
| What is the emerging role of immunotherapy?
For patients with recurrent/persistent or metastatic HNSCC who have had disease progression despite primary platinumcontaining therapy, new immunotherapy agents are now a standard of care option for second-line therapy. Two monoclonal antibodies directed against programmed death-1 (PD-1) receptor, pembrolizumab and nivolumab, have received FDA approval for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Immunotherapy engages and/or enhances immune system function leading to tumor eradication or long-term growth inhibition. Recent advancements in immunotherapy for HNSCC have focused on inhibition of PD-1/PD-L1. The PD-1 receptor is a cell membrane receptor expressed on antigen-stimulated T cells, B cells, natural killer T cells, and dendritic cells. [102] [103] [104] In normal tissues, activation of PD-1 results in inhibition and apoptosis of immune cells, largely utilized to enhance self-tolerance by T cells and prevent autoimmune reactions. Binding of PD-1 receptors to its ligands, PD-L1 and PD-L2, suppresses the immune response by inhibiting T cell proliferation, cytokine release, and cytotoxicity. 102, 103, 105 Tumor cells with abnormal PD-L1 expression activate the PD-1 receptor, suppressing cytotoxic T cells and avoiding recognition and elimination by the immune system. Anti PD-1 receptor therapies represent a form of reactivating the immune system to attack the tumor by blocking interaction between PD-1 receptors and its ligands. Multiple studies have examined the expression of the programmed death receptor ligand PD-L1 in HNSCC across multiple primary sites revealing expression levels between 46% and 100% depending on the staining method, fixation, and site. 113 One hundred thirty-two patients were enrolled and, after a medial follow-up of 9 months, the ORR was 18%. Similarly, an additional PD-1 monoclonal antibody, nivolumab, gained approval from the FDA in November 2016 for the same indication as pembrolizumab. 114 Ferris et al 115 investigated the use of nivolumab in HNSCC in a phase III trial. In that study, 361 patients with recurrent or metastatic disease were enrolled comparing nivolumab to standard single-agent therapy (using cetuximab, methotrexate, or docetaxel). In the nivolumab group, the median OS was improved versus the standard-therapy group, 7.5 months and 5.1 months, respectively. Although recent top line data from the KEYNOTE-040 phase III study, released in June 2017, demonstrated that pembrolizumab failed to meet its prespecified primary specified endpoint of OS, 116 both nivolumab and pembrolizumab are under extensive investigation with multiple ongoing trials assessing their utility in combination with current therapy for HNSCC. Regimens combining immunotherapy with other modalities will likely further improve outcomes. 
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